Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 in Refractory Focal Onset Epilepsy
NCT06132893Phase 3Active, not recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of opakalim in focal epilepsy, sponsored by Biohaven Ltd.. Started Mar 2024; status: active, not recruiting.
02
Drugs
opakalim
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT06132893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132893.